If you've searched how to get retatrutide in Australia in the last few months, you've probably hit the same wall everyone else does: a wave of headlines about record-breaking weight loss, followed by the flat reality that no Australian pharmacy can legally dispense the drug. As of August 2026, retatrutide — Eli Lilly's investigational GIP + GLP-1 + glucagon "triple-G" agonist — is not approved by the TGA, or by any regulator anywhere in the world.

But "not approved" doesn't mean "no pathway". Australia has a formal, well-documented set of access routes for unapproved medicines, and understanding which ones can and can't apply to retatrutide is genuinely useful — because the answer explains a lot about why 2027 is the year that changes.

How to Get Retatrutide in Australia: The Three Pathways That Actually Exist

The TGA maintains three main mechanisms for accessing an unapproved therapeutic good in this country. Here's how each one stacks up against retatrutide today.

1. Clinical trials (CTN/CTA schemes) — the only live door

Under the Clinical Trial Notification (CTN) and Clinical Trial Approval (CTA) schemes, an unapproved medicine can be lawfully imported and supplied in Australia for use in a trial, provided a Human Research Ethics Committee has approved the protocol and the sponsor has notified the TGA.

This is the mechanism that has allowed Australians to receive retatrutide at all. Lilly's TRIUMPH program is a multi-trial Phase 3 effort spanning obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnoea and cardiovascular disease, and several of those studies have run sites in Australia. The registries to check are the Australian New Zealand Clinical Trials Registry (ANZCTR) at anzctr.org.au and ClinicalTrials.gov, filtered by country and by "recruiting" status.

The honest caveat: entry criteria are narrow (typically BMI thresholds, age ranges and exclusions around diabetes status or recent weight-loss medication), sites cluster around capital cities, and you may be randomised to placebo or to a comparator like tirzepatide rather than retatrutide. More detail on the program is in our clinical trials breakdown.

2. The Special Access Scheme and Authorised Prescriber — structurally blocked, not just "hard"

This is the part most articles get wrong. The Special Access Scheme (SAS) and the Authorised Prescriber scheme let a doctor supply an unapproved medicine to an individual patient with a serious condition. People assume it's a matter of finding a sympathetic GP.

It isn't. SAS is an authorisation pathway, not a supply pathway. Even with approval in hand, a prescriber still has to source the actual product from somewhere legitimate — and for an investigational molecule still inside its registrational program, the sponsor supplies it to trial sites, not to individual clinicians. There is no commercial retatrutide presentation, no approved Product Information, no pack. That's why SAS realistically opens only once a product exists in a market somewhere. Our Australia access page tracks that sequence.

3. The Personal Importation Scheme — depends on a legitimate overseas prescription

Australia's personal import rules allow limited quantities of some medicines for personal use with a valid prescription from an Australian-registered practitioner. Again, the constraint is upstream: there's currently no approved retatrutide product in any overseas market to be prescribed. This pathway becomes relevant only after a regulator somewhere signs off.

Why 2027 Is the Real Answer

The regulatory clock is now visible. Lilly has said it intends to lodge its first major filing for retatrutide with the US FDA in the first quarter of 2027, with typical review timelines putting a possible US decision in late 2027 or 2028. TGA submissions are separate and generally follow, then the Pharmaceutical Benefits Advisory Committee process determines whether it lands on the PBS or sits as a private script.

So the practical picture for Australians is this: until a filing turns into an approval and a launch, trial participation is the only supervised route — and the trial window narrows as the program completes. TRIUMPH-1 and TRIUMPH-4 have reported; a head-to-head study against tirzepatide is slated for later in the program.

What the Data Says You'd Be Waiting For

The reason interest is this intense: in TRIUMPH-1, participants on the 12mg dose lost an average of 28.3% of body weight over 80 weeks, and 45.3% of participants achieved at least 30% weight loss — a threshold historically associated with bariatric surgery. In a prespecified blinded extension of participants with a baseline BMI of 35 or higher, average loss reached 30.3% (about 85 lb / 38.5 kg) at 104 weeks, with no clear plateau.

For context on how that compares with what's already available here: Ozempic and Wegovy are semaglutide, which targets one receptor; Mounjaro and Zepbound are tirzepatide, targeting two. Retatrutide adds glucagon receptor activity, which is thought to increase energy expenditure on top of appetite suppression. See what is retatrutide for the mechanism, and our safety page for the tolerability profile — predominantly gastrointestinal side effects, consistent with the incretin class.

What to Do in the Meantime

  • Talk to your GP about currently TGA-approved options. With roughly 66.8% of Australian adults living with overweight or obesity, obesity medicine is now a mainstream part of primary care here.
  • Check ANZCTR and ClinicalTrials.gov periodically if trial participation appeals to you, and take the participant information sheet to your own doctor before consenting.
  • Join our free updates list and we'll email you when Australian regulatory milestones actually happen — filing, evaluation, decision, PBS listing — rather than when the next overseas headline lands.

FAQ

How do I get retatrutide in Australia right now?

The only supervised, lawful route is enrolment in a clinical trial with an Australian site, run under the TGA's CTN or CTA schemes. Check the ANZCTR (anzctr.org.au) and ClinicalTrials.gov for recruiting TRIUMPH studies, and note that eligibility criteria are strict and randomisation may assign you to placebo or a comparator drug.

Can my doctor prescribe retatrutide through the Special Access Scheme?

Not in practice. SAS authorises a doctor to use an unapproved medicine, but it doesn't create a supply of it — and retatrutide has no commercial presentation anywhere in the world yet, because the sponsor supplies it only to trial sites.

When will retatrutide be available in Australia?

No date is confirmed. Lilly has signalled its first major regulatory filing in early 2027, and TGA registration plus any PBS listing would follow separately, so Australian availability is realistically a 2028-or-later proposition.

Is retatrutide approved by the TGA?

No. Retatrutide is investigational and is not approved by the TGA or by any other regulator, and it is not on the PBS.

Sources

Disclaimer: This article is general information only and is not medical advice. Retatrutide is an investigational medicine that is not approved by the TGA and is not available on prescription in Australia. Always speak with your GP or a qualified health professional about weight management options that are appropriate for you. retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.